What is IGF-1 LR3?
First, the plain version. Your body makes a natural hormone called IGF-1 — short for "insulin-like growth factor 1." A hormone is just a chemical messenger that travels in your blood. IGF-1 is one of the main signals that tells your body to build and grow tissue, and it is part of how growth hormone does its job.
IGF-1 LR3 (you will also see it written "Long R3 IGF-1") is a man-made, tweaked version of that natural hormone. Scientists changed two things about it. They added a small string of extra building blocks to one end, and they swapped a single building block in the chain. The point of those changes was to make it last much longer in the body and act more strongly.
Here is why those tweaks matter. Normally, most of your natural IGF-1 is grabbed and held by "carrier" proteins in your blood, which keeps it in check. The lab-made changes in IGF-1 LR3 stop those carriers from grabbing it well, so more of it stays active and it sticks around longer. In animal research, the analogue that binds poorly to those carrier proteins was actually cleared from the blood faster, yet still ended up roughly 1.5- to 2-fold more potent than ordinary IGF-1 for effects like body-weight gain and organ growth in rats (PMID 8708565). That is a finding in rats — it is not a recipe for using it in people, and it tells you nothing about a human dose.
The most important thing to understand up front: IGF-1 LR3 is a research chemical, not a medicine. It was made for laboratory study. It is sold "for research use only" and labeled "not for human consumption." That label is not a formality — it is the honest status of the compound.
Is there an official IGF-1 LR3 dose?
No. This is the heart of it, so it is worth being blunt: there is no official, approved, or "correct" dose of IGF-1 LR3 for a human being. None exists.
When a real medicine has a dose, that number comes from years of controlled human trials, review by regulators like the FDA, and a label that spells out who it is for, how much to take, and what to watch for. IGF-1 LR3 has been through none of that. It is not approved by the FDA for any use in people. There are no human dosing guidelines, because there is no body of human safety-and-effectiveness studies to build them from.
That absence is not a small gap you can fill in with a number from a forum. A dose is only meaningful next to the evidence that produced it — the trials that found what amount helped, what amount harmed, and in whom. For IGF-1 LR3 that evidence does not exist, so a number on its own would be a figure floating free of any of the testing that normally gives a dose meaning.
How is IGF-1 LR3 different from the approved IGF-1 medicine?
It is easy to get confused here, because a related thing genuinely is approved — and people sometimes point to it as if it settles the dose question. It does not. The approved product is a different molecule, for a different patient, given a different way.
That product is native recombinant human IGF-1, sold as mecasermin (brand name Increlex). It is the natural IGF-1 molecule, not the lab-modified "LR3" version. And its FDA approval is narrow: growth failure in children (aged two and older) with a rare, severe primary IGF-1 deficiency, or with a growth-hormone gene deletion who have developed antibodies to growth hormone. On its label, that deficiency is defined by strict numbers — for example a height and a baseline IGF-1 well below the normal range for the child's age.
Even its dose underlines the point. On the Increlex label the dose is written by body weight — a recommended start of 0.04 to 0.08 mg per kilogram twice daily by injection, adjusted up to a maximum of 0.12 mg/kg twice daily, all under a specialist who monitors the child closely. So "an IGF-1 medicine exists, and it has a dose" is true. But that dose belongs to native IGF-1, in children, for a specific deficiency, watched by a doctor. It says nothing about how much of the lab-modified LR3 analogue an adult should inject for muscle, recovery, or anti-aging — uses the approved medicine was never tested or approved for.
| Attribute | IGF-1 LR3 | Mecasermin (Increlex) |
|---|---|---|
| Molecule | Lab-modified long-acting IGF-1 analog | Native recombinant human IGF-1 |
| FDA approval | None — sold "for research use only" | Severe primary IGF-1 deficiency in children (age ≥2) |
| Established human dose | None exists | 0.04–0.08 mg/kg twice daily (max 0.12 mg/kg) |
| How it is dosed | No validated dose, in any unit | By body weight, under specialist monitoring |
What "doses" do people cite, and why treat them with caution?
If you search around, you will find very specific-looking numbers — microgram amounts, "once or twice a day," multi-week "cycles," and so on. They look authoritative because they are precise. Precision is not the same as proof.
Those figures come from bodybuilding forums, vendor pages, and informal lab write-ups passing the same numbers back and forth. They are not doses validated in human clinical trials, because those trials essentially do not exist for IGF-1 LR3. No regulator reviewed them. No safety study established that they are safe, and no effectiveness study established that they do what the forums claim. They are guesses that got repeated until they sounded official.
So please read any IGF-1 LR3 dose you see online for what it actually is: an unverified number, not medical advice and not a guideline. This article will not print specific dose figures, on purpose. Putting a number on the page would dress up guesswork as guidance, and there is no honest way to do that for an unapproved compound with no human dosing standard.
Why are scientists cautious about a strong "grow" signal?
To understand the worry, it helps to know what IGF-1 does. It is one of the body's main "build and divide" signals — it tells cells to grow and to multiply. That is exactly what you want during childhood growth or tissue repair. It is also, in principle, the kind of signal you do not want to crank up indefinitely, because growth that is helpful in the right place and time can be unwelcome elsewhere.
This is not just hand-waving. Large studies that measured people's own natural IGF-1 levels have found that higher levels track with a higher risk of certain cancers. A widely cited 2004 analysis in the Lancet, pooling many studies, reported that people in the upper part of the IGF-1 range had a modestly higher risk of prostate cancer (about a 49% higher odds comparing the 75th with the 25th percentile) and of premenopausal breast cancer (about 65% higher) than people lower in the range (PMID 15110491).
Read that carefully, because the honest framing matters. It is an association seen in people's natural levels — it is not proof that injecting a long-acting IGF-1 analogue causes cancer, and it does not put a number on any such risk. What it does do is explain why researchers treat the idea of deliberately and repeatedly pushing this particular signal upward, for non-medical reasons, with real caution rather than enthusiasm. "Plausibly powerful" and "safe to self-administer" are very different claims, and only the first has any support here.
What are the real risks and unknowns?
Because IGF-1 LR3 has never gone through human testing as a medicine, the honest answer to "is it safe, and at what dose?" is: nobody actually knows. That is the central risk. There is no human safety database to point to, and no monitoring system tracking what happens to people who use it.
There is also the product itself. Something sold "for research use only" is not made, tested, or released to medicine-grade standards. What is really in a given vial — whether it is the actual compound, how pure it is, whether the amount on the label is the amount inside, and whether it is sterile enough to inject — is not guaranteed by anyone. This is not a hypothetical worry. When researchers chemically analyzed injectable peptide products sold online without a prescription, the results were alarming: in one 2024 analysis of grey-market semaglutide, measured purity ran as low as 7.7% to 14.37% against a claimed 99%, and bacterial endotoxin — a contaminant that can cause fever and worse — was found in every sample tested (PMC11582493). Different compound, same unregulated supply chain, and the same lesson: the label cannot be trusted.
And the error runs in both directions. That same analysis found that the actual drug content in some products overshot the label by roughly 29% to 39% — so a buyer trusting the printed amount could just as easily get far more than expected as far less. For an everyday supplement that swing might be harmless. For an injectable that acts on a growth pathway, where the user is already guessing at an amount with no validated dose to anchor to, an unpredictable concentration turns "guessing the dose" into "guessing the dose of an unknown strength." There is no pharmacist, no quality lot release, and no recall mechanism standing between that vial and your bloodstream.
Then there is the biology covered above. IGF-1 is a powerful growth signal, and the general concern about pushing any strong "grow" signal too high for too long has not been resolved for IGF-1 LR3 in people, because the studies have not been done. "We do not know" is not the same as "it is fine."
Finally, if you compete in any tested sport, this matters concretely. Exogenous IGF-1 and its analogues are on the World Anti-Doping Agency (WADA) Prohibited List, banned at all times — in and out of competition — within the class of peptide hormones, growth factors and related substances. Using IGF-1 LR3 can mean a failed drug test and a sanction. That part is not gray.
Who should you actually talk to?
A licensed clinician — a doctor who can look at your actual health, your history, and your goals. Not a forum, not a vendor, and not an article on the internet, including this one.
If you are interested in IGF-1 LR3 because you are chasing something specific — more muscle, faster recovery, feeling younger — a real clinician can talk through what is actually known, what is not, and whether there is a legitimate, monitored path that fits your situation. They can also weigh your personal risk factors, the family history and existing conditions that a forum post knows nothing about, and order proper bloodwork before anything is decided. That is a conversation worth having with a person who is responsible for your safety, instead of acting alone on a number you found online.
Nothing here is medical advice, and PeptidePanel does not tell anyone to use IGF-1 LR3. The point of this page is the opposite: there is no approved dose, the compound is unapproved and largely untested in humans, and the right next step is a clinician, not a syringe.
Where PeptidePanel fits
PeptidePanel does not sell, supply, source, or recommend IGF-1 LR3 or any other compound. It is a tracking tool, not a pharmacy and not a clinic.
If you are working with a licensed clinician on any protocol that they have prescribed and are monitoring, PeptidePanel is simply the place to keep that organized — recording the plan your clinician set, charting your lab results over time, and reminding you when something is due. The decisions stay with your clinician. The notebook stays tidy.